Skip to main content
. Author manuscript; available in PMC: 2021 Jun 2.
Published in final edited form as: Clin Cancer Res. 2017 Apr 5;23(15):4127–4137. doi: 10.1158/1078-0432.CCR-16-2818

Figure 1.

Figure 1.

PFS in DLBCL subtype populations after treatment with lenalidomide or IC. Kaplan–Meier estimates of PFS are shown for (A) overall population, (B) GCB DLBCL, and (C) non-GCB DLBCL analyzed by IHC, as well as (D) GCB DLBCL and (E) ABC DLBCL analyzed by GEP.